HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) -Post-Traumatic Epilepsy (PTE)

Status: Active_not_recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-PTE, to improve the quality of life and cognitive function in Service Members, Veterans and civilians with post traumatic epilepsy (PTE). This study will also assess the ability of the HOBSCOTCH-PTE program to improve quality of life in caregivers of PTE patients and to reduce caregiver burden.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18+

• Diagnosis of post traumatic epilepsy, with controlled or uncontrolled seizures

• Subjective memory complaints

• No changes in antiepileptic and antidepressant medication regimen for 1 month, however brief discontinuation of antiepileptic medicine for inpatient video EEG evaluation is acceptable

• Literate and proficient in English

• Telephone access

• Internet access

• Age 18+

• Caregivers to a patient with a confirmed diagnosis of PTE

• Literate and proficient in English

• Telephone access

• Internet access

Locations
United States
New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon
Time Frame
Start Date: 2022-03-21
Completion Date: 2026-02
Participants
Target number of participants: 160
Treatments
Experimental: PTE Participant Group 1
PTE Participant Group 1 will receive the HOBSCOTCH-PTE intervention consisting of 1:1 sessions delivered once per week including:~* 1 pre-HOBSCOTCH Session (on webcam)~* 1 educational session (on webcam)~* 6 telephone sessions~* 1 wrap-up session (webcam or telephone)
Other: PTE Participant Group 2
PTE Participant Group 2 will be on a 3-month wait list after which they will receive HOBSCOTCH-PTE consisting of 1:1 sessions delivered once per week including:~* 1 pre-HOBSCOTCH Session (on webcam)~* 1 educational session (on webcam)~* 6 telephone sessions~* 1 wrap-up session (webcam or telephone)
Experimental: PTE Caregiver Group 1
Caregiver Group 1 will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 1 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
Other: PTE Caregiver Group 2
Caregiver Group 2 will be on a 3 month wait list with their PTE patient after which time they will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 2 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
Related Therapeutic Areas
Epilepsy
Post-Traumatic Epilepsy
Sponsors
Collaborators: United States Department of Defense
Leads: Dartmouth-Hitchcock Medical Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Biperiden for Prevention of Epilepsy in Patients With Traumatic Brain Injury

Biperiden for Prevention of Epilepsy in Patients With Traumatic Brain Injury

Who is this study for: Patients with traumatic brain injury
Enrollment Status: Recruiting
Publish Date: March 26, 2024
Intervention Type: Drug, Other
Study Drug: Biperiden
Study Phase: Phase 3

Collaborative Care for Anxiety and Depression in Posttraumatic Epilepsy

Collaborative Care for Anxiety and Depression in Posttraumatic Epilepsy

Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable

Comparison of Levetiracetam Versus Lacosamide for Seizure Prevention in Moderate to Severe Traumatic Brain Injured Patients

Comparison of Levetiracetam Versus Lacosamide for Seizure Prevention in Moderate to Severe Traumatic Brain Injured Patients

Enrollment Status: Recruiting
Publish Date: April 27, 2025
Intervention Type: Drug
Study Phase: Phase 4
View All